- Home
- BATL vs RLMD Comparison
BATL vs RLMD Comparison
Compare BATL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- RLMD
- Stock Information
- Founded
- BATL 1987
- RLMD 2004
- Country
- BATL United States
- RLMD United States
- Employees
- BATL N/A
- RLMD N/A
- Industry
- BATL Oil & Gas Production
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- RLMD Health Care
- Exchange
- BATL Nasdaq
- RLMD Nasdaq
- Market Cap
- BATL 109.4M
- RLMD 110.6M
- IPO Year
- BATL N/A
- RLMD N/A
- Fundamental
- Price
- BATL $6.67
- RLMD $3.01
- Analyst Decision
- BATL
- RLMD Hold
- Analyst Count
- BATL 0
- RLMD 2
- Target Price
- BATL N/A
- RLMD $7.50
- AVG Volume (30 Days)
- BATL 48.1K
- RLMD 117.3K
- Earning Date
- BATL 11-26-2024
- RLMD 11-07-2024
- Dividend Yield
- BATL N/A
- RLMD N/A
- EPS Growth
- BATL N/A
- RLMD N/A
- EPS
- BATL N/A
- RLMD N/A
- Revenue
- BATL $191,482,000.00
- RLMD N/A
- Revenue This Year
- BATL $2.21
- RLMD N/A
- Revenue Next Year
- BATL N/A
- RLMD N/A
- P/E Ratio
- BATL N/A
- RLMD N/A
- Revenue Growth
- BATL N/A
- RLMD N/A
- 52 Week Low
- BATL $2.48
- RLMD $1.88
- 52 Week High
- BATL $9.69
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- BATL 59.41
- RLMD 31.18
- Support Level
- BATL $6.49
- RLMD $3.06
- Resistance Level
- BATL $6.84
- RLMD $3.43
- Average True Range (ATR)
- BATL 0.12
- RLMD 0.20
- MACD
- BATL -0.07
- RLMD -0.05
- Stochastic Oscillator
- BATL 45.00
- RLMD 6.61
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.